References
- BourneRRJonasJBFlaxmanSRPrevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990–2010Br J Ophthalmol20149862963824665132
- CongdonNVingerlingJRKleinBEPrevalence of cataract and pseudophakia/aphakia among adults in the United StatesArch Ophthalmol200412248749415078665
- ThyleforsBThe World Health Organization’s programme for the prevention of blindnessInt Ophthalmol1990142112192188924
- Preferred Practice Pattern® GuidelinesCataract in the adult eyeAmerican Academy of Ophthalmology2011 Available from: http://www.aao.org/pppAccessed September, 2016
- AsbellPADualanIMindelJBrocksDAhmadMEpsteinSAge-related cataractLancet200536559960915708105
- GrobSRGonzalez-GonzalezLADalyMKManagement of mydriasis and pain in cataract and intraocular lens surgery: review of current medications and future directionsClin Ophthalmol201481281128925061276
- O’BrienTPEmerging guidelines for use of NSAID therapy to optimize cataract surgery patient careCurr Med Res Opin2005211131113716004683
- DonnenfeldEDDose-response curve of a topical NSAID as a surgical tool before cataract surgeryAmerican Society of Cataract and Refractive Surgery – American Society of Ophthalmic Administrators (ASCRS-ASOA) Symposium & CongressApril 16–20, 2005Washington, DC
- DrewsRCKatsevDAOcufen and pupillary dilation during cataract surgeryJ Cataract Refract Surg1989154454482778693
- KimSJFlachAJJampolLMNonsteroidal anti-inflammatory drugs in ophthalmologySurv Ophthalmol20105510813320159228
- SrinivasanRMadhavarangaTopical ketorolac tromethamine 0.5% versus diclofenac sodium 0.1% to inhibit miosis during cataract surgeryJ Cataract Refract Surg20022851752011973101
- ColinJThe role of NSAIDs in the management of postoperative ophthalmic inflammationDrugs2007671291130817547472
- MargalitEKuglerLJBrummMVThe safety of intraocular ketorolac in rabbitsInvest Ophthalmol Vis Sci2006472093209916639020
- WaterburyLDGalindoDVillanuevaLOcular penetration and anti-inflammatory activity of ketorolac 0.45% and bromfenac 0.09% against lipopolysaccharide-induced inflammationJ Ocul Pharmacol Ther20112717317821351868